Yesim Dargaud

List of Publications by Year
in descending order

118	3,919	136885	133188
papers	citations	32 h-index	59 g-index

125	125	125	3363
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thrombosis and Haemostasis, 2005, 93, 475-480.	1.8	295
2	An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine, 2015, 21, 492-497.	15.2	247
3	Hypofibrinolytic state and high thrombin generation may play a major role in SARSâ€COV2 associated thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 2215-2219.	1.9	225
4	Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax, 2021, 76, 970-979.	2.7	210
5	Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood, 2013, 121, 1944-1950.	0.6	140
6	Use of calibrated automated thrombinography Â± thrombomodulin to recognise the prothrombotic phenotype. Thrombosis and Haemostasis, 2006, 96, 562-567.	1.8	130
7	Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. British Journal of Haematology, 2007, 139, 303-309.	1.2	129
8	Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood, 2010, 116, 5734-5737.	0.6	118
9	Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: An international multicentre study. Thrombosis Research, 2012, 130, 929-934.	0.8	110
10	Whole-Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay. Clinical Chemistry, 2012, 58, 1252-1259.	1.5	100
11	Mechanisms and monitoring of bypassing agent therapy. Journal of Thrombosis and Haemostasis, 2012, 10, 1478-1485.	1.9	91
12	Standardisation of thrombin generation test - which reference plasma for TGT?: An international multicentre study. Thrombosis Research, 2010, 125, 353-356.	0.8	90
13	Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia, 2005, 11, 552-558.	1.0	88
14	Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1704-1707.	1.9	80
15	Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. Thrombosis and Haemostasis, 2016, 116, 638-650.	1.8	78
16	Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica, 2018, 103, e181-e183.	1.7	78
17	Tests of global haemostasis and their applications in bleeding disorders. Haemophilia, 2010, 16, 85-92.	1.0	75
18	A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. British Journal of Haematology, 2009, 145, 825-835.	1.2	72

#	Article	IF	Citations
19	Haemophilia and thrombophilia: an unexpected association!. Haemophilia, 2004, 10, 319-326.	1.0	69
20	Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia, 2010, 16, 771-777.	1.0	61
21	Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica, 2007, 92, 1639-1646.	1.7	58
22	Reversal of the inhibitory effect of Fondaparinux on Thrombin generation by rFVIIa, aCCP and PCC. Thrombosis Research, 2009, 123, 796-798.	0.8	57
23	Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. Thrombosis Research, 2015, 136, 125-130.	0.8	57
24	Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor. Journal of Thrombosis and Haemostasis, 2006, 4, 1160-1161.	1.9	53
25	New developments in laboratory diagnosis and monitoring. Haemophilia, 2010, 16, 61-66.	1.0	50
26	Increased blood viscosity and red blood cell aggregation in patients with COVIDâ€19. American Journal of Hematology, 2022, 97, 283-292.	2.0	45
27	Diagnosis and management challenges in patients with mild haemophilia A and discrepant <scp>FVIII</scp> measurements. Haemophilia, 2014, 20, 550-558.	1.0	43
28	Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thrombosis and Haemostasis, 2006, 96, 562-7.	1.8	41
29	Seventyâ€two total knee arthroplasties performed in patients with haemophilia using continuous infusion. Vox Sanguinis, 2013, 104, 135-143.	0.7	39
30	Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation. Blood, 2015, 125, 1497-1501.	0.6	39
31	Towards a recommendation for the standardization of the measurement of plateletâ€dependent thrombin generation. Journal of Thrombosis and Haemostasis, 2011, 9, 1859-1861.	1.9	37
32	Basic aspects of bypassing agents. Haemophilia, 2006, 12, 48-53.	1.0	36
33	Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study. Journal of Thrombosis and Haemostasis, 2017, 15, 897-906.	1.9	33
34	Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 1372-1378.	1.9	32
35	Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays. Thrombosis Research, 2017, 153, 7-13.	0.8	29
36	Thrombin generation testing in haemophilia comprehensive care centres. Haemophilia, 2010, 16, 223-230.	1.0	28

#	Article	IF	Citations
37	Individualized PKâ€based prophylaxis in severe haemophilia. Haemophilia, 2018, 24, 3-17.	1.0	28
38	Management of pregnant women with increased risk of venous thrombosis. International Journal of Gynecology and Obstetrics, 2005, 90, 203-207.	1.0	27
39	New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia, 2008, 14, 20-27.	1.0	27
40	Endogenous thrombin potential, prothrombin fragment 1+2 and D-dimers during pregnancy. Thrombosis and Haemostasis, 2010, 103, 469-471.	1.8	27
41	Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis. Cerebrovascular Diseases, 2019, 48, 32-37.	0.8	27
42	Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots. Haemophilia, 2011, 17, 957-961.	1.0	26
43	Spontaneous proximal deep vein thrombosis in a patient with severe haemophilia A. Blood Coagulation and Fibrinolysis, 2003, 14, 407-409.	0.5	24
44	Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study. Journal of Thrombosis and Haemostasis, 2008, 6, 962-968.	1.9	23
45	Monitoring platelet dependent thrombin generation in mice. Thrombosis Research, 2010, 126, 436-441.	0.8	23
46	Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. Journal of Thrombosis and Haemostasis, 2011, 9, 1549-1555.	1.9	23
47	Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. Journal of Thrombosis and Haemostasis, 2013, 11, 1043-1052.	1.9	23
48	Use of the Thrombin Generation Test to Evaluate Response to Treatment With Recombinant Activated Factor VII. Seminars in Hematology, 2008, 45, S72-S73.	1.8	22
49	Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq^{Â®} (humanâ€cl rh<scp>FVIII</scp>) in previously treated patients with severe haemophilia A. Haemophilia, 2018, 24, 619-627.	1.0	22
50	Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency. Journal of Thrombosis and Haemostasis, 2010, 8, 286-293.	1.9	20
51	Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications. Thrombosis Research, 2012, 130, e266-e273.	0.8	18
52	Global haemostasis and point of care testing. Haemophilia, 2012, 18, 81-88.	1.0	18
53	Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Thrombosis and Haemostasis, 2006, 95, 593-599.	1.8	17
54	Case Scenario: Management of Trauma-induced Coagulopathy in a Severe Blunt Trauma Patient. Anesthesiology, 2013, 119, 191-200.	1.3	17

#	Article	IF	Citations
55	Onâ€demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia, 2012, 18, 255-262.	1.0	16
56	The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia. Haemophilia, 2012, 18, 818-823.	1.0	16
57	A new paradigm for personalized prophylaxis for patients with severe haemophilia A. Haemophilia, 2020, 26, 228-235.	1.0	16
58	Successive bleeding and thrombotic complications in a patient with afibrinogenemia: A case report. Thrombosis Research, 2011, 128, 296-298.	0.8	14
59	Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity. Thrombosis Research, 2015, 135, 1017-1024.	0.8	14
60	Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: Are these results really discordant?. Thrombosis and Haemostasis, 2007, 97, 675-676.	1.8	14
61	Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy. British Journal of Haematology, 2003, 123, 342-345.	1.2	13
62	Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic. Thrombosis Research, 2020, 192, 52-60.	0.8	13
63	Platelet-dependent thrombography: a method for diagnostic laboratories. British Journal of Haematology, 2006, 134, 323-325.	1.2	12
64	Intraindividual thrombin generation measurement variability in healthy adults over a one year period. Thrombosis Research, 2009, 124, 237-238.	0.8	12
65	An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy. Blood Coagulation and Fibrinolysis, 2008, 19, 447-452.	0.5	11
66	Dose tailoring of human cell lineâ€derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. British Journal of Clinical Pharmacology, 2019, 85, 771-781.	1.1	11
67	Study of the relationship between the suprascapular artery and the brachial plexus. Surgical and Radiologic Anatomy, 2002, 24, 108-112.	0.6	10
68	Acquired Glanzmann's Thrombasthenia Associated With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2005, 27, 554-557.	0.3	9
69	Haemophilia therapies. Expert Opinion on Biological Therapy, 2007, 7, 651-663.	1.4	9
70	Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency. Thrombosis Journal, 2018, 16, 6.	0.9	8
71	Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice. Thrombosis and Haemostasis, 2019, 119, 1956-1967.	1.8	8
72	Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study. Journal of Thrombosis and Haemostasis, 2020, 18, 584-592.	1.9	8

#	Article	IF	Citations
73	Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations. Thrombosis and Haemostasis, 2006, 95, 593-9.	1.8	8
74	Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis. TH Open, 2019, 03, e273-e285.	0.7	7
75	Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX. Thrombosis and Haemostasis, 2018, 118, 2053-2063.	1.8	6
76	Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?. PLoS ONE, 2017, 12, e0188213.	1.1	6
77	A singleâ€centre study of management of pregnant women with von Willebrand disease. Haemophilia, 2019, 25, e54-e57.	1.0	5
78	Response to â€œStudies on hemostasis in COVIDâ€19 deserve careful reporting of the laboratory methods, their significance and their limitationâ€• Donâ€™t throw the baby out with the bathwater. Journal of Thrombosis and Haemostasis, 2020, 18, 3124-3126.	1.9	5
79	Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?. Thrombosis Journal, 2020, 18, 15.	0.9	5
80	Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12631.	1.0	5
81	Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: are these results really discordant?. Thrombosis and Haemostasis, 2007, 97, 675-6.	1.8	5
82	Multiple arterial thromboses in a patient with primary antiphospholipid syndrome receiving a bromocriptine therapy. Lupus, 2004, 13, 957-960.	0.8	4
83	In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuHâ€7. Haemophilia, 2015, 21, e317-21.	1.0	4
84	Challenges of the management of severe hemophilia A with inhibitors. Blood Coagulation and Fibrinolysis, 2015, 26, 940-945.	0.5	4
85	The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?. Leukemia and Lymphoma, 2019, 60, 2572-2575.	0.6	4
86	Pregnancy and thrombosis: Adrenal vein thrombosis. A retrospective descriptive study of 14 cases. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 233, 38-42.	0.5	4
87	Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia. Acta Haematologica, 2021, 144, 308-313.	0.7	4
88	Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutation. British Journal of Haematology, 2016, 174, 993-996.	1.2	3
89	The modification of the thrombin generation assay for the clinical assessment of hypercoagulability in patients receiving heparin therapy. International Journal of Laboratory Hematology, 2021, , .	0.7	3
90	Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence. Journal of Blood Medicine, 2021, Volume 12, 1031-1036.	0.7	3

#	Article	IF	Citations
91	Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency. Thrombosis Research, 2005, 116, 483-489.	0.8	2
92	Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women. A rebuttal. Thrombosis Research, 2008, 122, 715-716.	0.8	2
93	Pregnancy-related thrombosis risk in patients with protein C deficiency and comparison with pregnant women with heterozygous factor V Leiden mutation. Blood Coagulation and Fibrinolysis, 2020, 31, 55-59.	0.5	2
94	Quelle place pour la biologie chez les patients traitÃ©s par anticoagulants oraux directs ?. Revue Francophone Des Laboratoires, 2020, 2020, 42-47.	0.0	2
95	Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study. Haemophilia, 2021, 27, 1002-1006.	1.0	2
96	Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective singleâ€•centre study. Haemophilia, 2022, 28, 301-307.	1.0	2
97	OC-13 Enhanced expression of Mda-9/syntenin induced through the tissue-factor pathway in melanoma promotes tumor cell migration and invasion. Thrombosis Research, 2010, 125, S164.	0.8	1
98	Genotyping might help therapeutic decisionâ€•making in patients with von Willebrand disease type 2 B. Haemophilia, 2016, 22, e439-43.	1.0	1
99	The potential value of thrombin generation assay in the diagnosis of FV inhibitors. International Journal of Laboratory Hematology, 2019, 41, e117-e120.	0.7	1
100	Recombinant Porcine Factor VIII Corrects Thrombin Generation and Improves Clot Structure In Vitro in Plasma Containing Anti-Factor VIII Inhibitory Antibodies. Blood, 2011, 118, 2282-2282.	0.6	1
101	Individually Tailored Prophylaxis Using a Risk Score for the Management of Pregnant Women with Increased Risk of Venous Thromboembolism. Blood, 2015, 126, 889-889.	0.6	1
102	The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?. Blood, 2014, 124, 2037-2037.	0.6	1
103	P3 A score based prevention strategy of venous thromboembolism in pregnant women. Thrombosis Research, 2009, 123, S139-S140.	0.8	0
104	ParticularitÃ©s de lâ€™hÃ©mostase chez la femme enceinte et maniement des antithrombotiques. Praticien En Anesthesie Reanimation, 2009, 13, 404-410.	0.0	0
105	C0355 Pregnancy related thrombosis risk in patients with protein C deficiency. Thrombosis Research, 2012, 130, S123.	0.8	0
106	OC-14 Pregnancy related thrombosis risk in patients with protein C deficiency. Thrombosis Research, 2013, 131, S74.	0.8	0
107	Diagnostic biologique du syndrome des antiphospholipides. Revue Francophone Des Laboratoires, 2020, 2020, 34-41.	0.0	0
108	Inactivation-Resistant Recombinant Factor VIII Exhibits Superior Thrombin Generation Capacity in Comparison to Wild-Type and B Domain-Deleted Factor VIII.. Blood, 2006, 108, 1604-1604.	0.6	0

#	Article	IF	Citations
109	How can We Predict Efficacy of rFVIIa in Hemophilia Patients with Inhibitors?. Blood, 2009, 114, 3487-3487.	0.6	0
110	Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.. Blood, 2009, 114, 4443-4443.	0.6	0
111	Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.. Blood, 2009, 114, 4202-4202.	0.6	0
112	The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation. Blood, 2011, 118, 541-541.	0.6	0
113	Lâ€™aspirine a-t-elle une place dans la prÃ©vention secondaire de la maladie thromboembolique veineuseÂ?. Hematologie, 2013, 19, 94-94.	0.0	0
114	Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A. Blood, 2016, 128, 1410-1410.	0.6	0
115	Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI). Blood, 2018, 132, 2482-2482.	0.6	0
116	Hemostatic Effect of the Combination of Factor VIII Concentrate with Tranexamic Acid (TXA) in the Prophylactic Setting in Severe Hemophilia a. Blood, 2018, 132, 2490-2490.	0.6	0
117	Personalized treatment for haemophilia. Hematologie, 2020, 26, 162-172.	0.0	0
118	Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	0